Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia

Trial Profile

Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs LY 3202626 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms NAVIGATE-AD
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Aug 2017 Planned number of patients changed from 500 to 380.
    • 11 Aug 2017 Planned End Date changed from 1 Aug 2019 to 1 Jun 2019.
    • 11 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top